Association of the Chantix Recall With US Prescribing of Varenicline and Other Medications for Nicotine Dependence

Adam Edward Lang; Urvashi Patel; Jonathan Fitzpatrick; Tiffany Lee; Margo McFarland; Chester B Good

doi:10.1001/jamanetworkopen.2022.54655

Association of the Chantix Recall With US Prescribing of Varenicline and Other Medications for Nicotine Dependence

JAMA Netw Open. 2023 Feb 1;6(2):e2254655. doi: 10.1001/jamanetworkopen.2022.54655.

Authors

Adam Edward Lang^{1

2}, Urvashi Patel³, Jonathan Fitzpatrick⁴, Tiffany Lee³, Margo McFarland⁵, Chester B Good⁶

Affiliations

¹ Department of Primary Care, McDonald Army Health Center, Ft Eustis, Virginia.
² Department of Family Medicine and Population Health, Virginia Commonwealth University School of Medicine, Richmond.
³ Research Institute Department, Evernorth Health Services, St Louis, Missouri.
⁴ Department of Client Solution Product Strategy, Evernorth Health Services, St Louis, Missouri.
⁵ Pharmacy Services, Insurance Services Division, UPMC Health Plan, Pittsburgh, Pennsylvania.
⁶ Centers for High Value Health Care and Value Based Pharmacy Initiatives, Insurance Services Division, UPMC Health Plan, Pittsburgh, Pennsylvania.

PMID: 36745457
DOI: 10.1001/jamanetworkopen.2022.54655

No abstract available

Plain language summary

This cross-sectional study evaluates the association between the 2021 varenicline tartrate recall and prescribing of varenicline and other medications for nicotine dependence in a large US national patient cohort.

MeSH terms

Humans
Nicotinic Agonists / therapeutic use
Smoking Cessation*
Tobacco Use Disorder* / drug therapy
Varenicline / therapeutic use

Substances

Varenicline
Nicotinic Agonists